

**Committee on Energy and Commerce**  
**U.S. House of Representatives**  
Witness Disclosure Requirement - "Truth in Testimony"  
Required by House Rule XI, Clause 2(g)(5)

<b>1. Your Name:</b> Janet Woodcock		
<b>2. Your Title:</b> Director, Center for Drug Evaluation and Research		
<b>3. The Entity(ies) You are Representing:</b> The United States Food and Drug Administration		
<b>4. Are you testifying on behalf of the Federal, or a State or local government entity?</b> Federal	<b>Yes</b> X	<b>No</b>
<b>5. Please list any Federal grants or contracts, or contracts or payments originating with a foreign government, that you or the entity(ies) you represent have received on or after January 1, 2015. Only grants, contracts, or payments related to the subject matter of the hearing must be listed.</b>  N/A		
<b>6. Please attach your curriculum vitae to your completed disclosure form.</b>		

Signatures



Date: 3/1/17



## **BIOGRAPHICAL INFORMATION**

### **Janet Woodcock, M.D.**

Janet Woodcock is Director of the Center for Drug Evaluation and Research (CDER), and Acting Director, Office of New Drugs at the Food and Drug Administration (FDA). Dr. Woodcock first joined CDER in 1994. For three years, from 2005 until 2008, she served FDA's Commissioner, holding several positions, including as Deputy Commissioner and Chief Medical Officer, Deputy Commissioner for Operations, and Chief Operating Officer. Her responsibilities involved oversight of various aspects of scientific and medical regulatory operations. Before joining CDER, Dr. Woodcock served as Director, Office of Therapeutics Research and Review, and Acting Deputy Director in FDA's Center for Biologics Evaluation and Research. Dr. Woodcock received her M.D. from Northwestern Medical School and completed further training and held teaching appointments at the Pennsylvania State University and the University of California in San Francisco. She joined FDA in 1986.